MDxHealth Completes EUR 18 Million ($24M) Equity Raise

MDxHealth Completes EUR 18 Million ($24M) Equity Raise 
LIEGE, BELGIUM -- (Marketwired) -- 06/25/13 --  MDxHealth SA
(EURONEXT BRUSSELS: MDXH), a leading molecular diagnostics company
that develops and commercializes epigenetic tests to support the
diagnosis and treatment of cancer patients, announced today that it
successfully raised an aggregate amount of EUR 18 million in a
private placement through the issuance of 8,737,683 new shares at a
subscription price of EUR 2.06 per share (which represents the
average closing price of the company's shares during the 30 preceding
calendar days). Certain funds managed by Valiance Asset Management
Ltd participated in the private placement for a total amount of
4,368,932 new shares and Biovest Comm. VA, the investment company of
Rudi Marien, participated in the private placement for a total amount
of 2,427,184 new shares. The remaining 1,941,747 new shares were
underwritten by Petercam who acted as sole lead manager in the
transaction, and will be placed with a limited group of investors. 
The net proceeds of the private placement will be used to support and
scale-up the Company's U.S.-based CLIA-registered commercial
laboratory, its US-based sales and marketing efforts, European and
global commercial efforts for its Clinical Molecular Diagnostics
(ClinicalMDx) and Pharmaco Molecular Diagnostics (PharmacoMDx)
solutions and services to clinicians and pharmaceutical customers,
and to accelerate proprietary product development. 
The 1,941,747 new shares underwritten by Petercam with the view to be
placed with investors are expected to be admitted to listing on NYSE
Euronext Brussels immediately following their issuance. The other new
shares are expected to be listed in the near future following the
approval and publication of a listing prospectus. 
"This financing marks a major milestone in the growth and success of
our Company," stated Dr. Jan Groen, CEO of MDxHealth. "In response to
the increasing demand for our ConfirmMDx(TM) for Prostate Cancer test
in the U.S., we will expand our commercial efforts by investing in
personnel and infrastructure to ensure we are well positioned for new
tests emerging from our product pipeline. We will also use proceeds
to further emphasize our global commercialization efforts, offering
our cutting edge products and services to clinical and pharmaceutical
customers, with the goal of accelerating and diversifying our revenue
base." 
About MDxHealth(R) 
 MDxHealth is a molecular diagnostics company
that develops and commercializes advanced epigenetic tests for cancer
assessment and the personalized treatment of patients. The Company's
first commercial product, ConfirmMDx(TM) for Prostate Cancer, has
been shown to help distinguish patients who have a true-negative
biopsy from those who may have undetected cancer. MDxHealth helps to
address a large and growing unmet medical need for better cancer
diagnosis and treatment information. The company has a proprietary
platform and a strong epigenetic product pipeline focused on the
development of products for prostate, brain and lung cancers. The
company is based in Irvine, California with a European headquarters
in Liege, Belgium. For more information visit MDxHealth's website at
www.mdxhealth.com. 
Important notice 
This press release contains forward-looking statements and estimates
with respect to the anticipated future performance of MDxHealth and
the market in which it operates. Such statements and estimates are
based on assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable but may
not prove to be correct. Actual events are difficult to predict, may
depend upon factors that are beyond the company's control, and may
turn out to be materially different. MDxHealth expressly disclaims
any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any
such statement is based unless required by law or regulation. This
press release does not constitute an offer or invitation for the sale
or purchase of securities or assets of MDxHealth in any jurisdiction.
No securities of MDxHealth may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933, as
amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. securities laws. 
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are
trademarks or registered trademarks of MDxHealth SA. All other
trademarks and service marks are the property of their respective
owners. 
To access the PDF version, please click here:
http://hugin.info/137314/R/1711813/567989.pdf 
For more information: 
Dr. Jan Groen, CEO
MDxHealth
US: +1 949 812 6979
BE: +32 4 364 20 70
info@mdxhealth.com  
Mike Sinclair
Halsin Partners
UK: +44 20 7318 2955
Cell: +44 7968 022075
msinclair@halsin.com  
Seth Lewis
The Trout Group
US: +1 646 378 2952
slewis@troutgroup.com 
 
 
Press spacebar to pause and continue. Press esc to stop.